Case Report: Pediatric ACTH-secreting pituitary adenoma presenting with hypertension and anuria - Scorecard - MDSpire

Case Report: Pediatric ACTH-secreting pituitary adenoma presenting with hypertension and anuria

  • By

  • Jiaxin Li

  • Wei Xia

  • Mengxing Wu

  • July 8, 2026

  • 0 min

Share

Clinical Scorecard: Pediatric Case Study: Hypertension and Anuria Associated with ACTH-Secreting Pituitary Adenoma

At a Glance

CategoryDetail
ConditionACTH-secreting pituitary adenoma
Key MechanismsPituitary apoplexy due to acute hemorrhage or infarction within the tumor.
Target PopulationPediatric patients, specifically a 13-year-old boy.
Care SettingEmergency department and surgical intervention.

Key Highlights

  • Severe headache, anuria, and hypertensive crisis in a pediatric patient.
  • Elevated ACTH and disrupted cortisol rhythm confirmed diagnosis.
  • MRI showed a cystic lesion consistent with apoplexy.
  • Histopathology confirmed ACTH-secreting adenoma.
  • Successful management with transsphenoidal resection and hormone replacement.

Guideline-Based Recommendations

Diagnosis

  • MRI is pivotal for initial evaluation of pituitary adenomas.
  • Histopathology is necessary for definitive diagnosis.

Management

  • Early surgical intervention is critical for favorable outcomes.
  • Hormonal management post-surgery is essential.

Monitoring & Follow-up

  • Regular follow-up for blood pressure, weight, kidney, and endocrine function.

Risks

  • Pituitary apoplexy is rare in microadenomas but can occur.

Patient & Prescribing Data

Pediatric patients with ACTH-secreting pituitary adenomas.

Transsphenoidal resection followed by hormone replacement therapy.

Clinical Best Practices

  • Consider differential diagnoses for acute headache and anuria in pediatric patients.
  • Monitor for signs of endocrine dysfunction in patients with pituitary adenomas.

Related Resources & Content

Original Source(s)

Case Report: Pediatric ACTH-secreting pituitary adenoma presenting with hypertension and anuria

  • by Jiaxin Li, Wei Xia, Mengxing Wu

  • July 8, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.